NASDAQ
16.78USD
0.00 (0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
0.20
52W range
14.68-25.32
Day range
16.47–17.26
Open
16.86
Prev close
16.78
Volume
3M
Avg volume
3.2M
Dividend
0.00
IPO
1997-06-04
https://www.proactiveinvestors.com/companies/news/1096081 · 7/27/2026+0.00
https://www.globenewswire.com/news-release/2026/07/13/3326258/0/en/Johnson-Fistel-PLLP-Investigates-Claims-on-Behalf-of-Long-Term-Shareholders-of-Sarepta-Therapeutics-Inc-SRPT.html · 7/13/2026-1.00
https://www.fool.com/investing/2026/07/11/2-beaten-down-stocks-that-still-arent-worth-buying/ · 7/11/2026-0.20
https://247wallst.com/investing/2026/07/10/ionis-pharmaceuticals-drops-another-9-as-bad-news-piles-up/ · 7/10/2026-0.60
https://www.newsfilecorp.com/release/300463/BioGene-Therapeutics-Inc.-Appoints-Ty-Howton-to-Board-of-Directors · 6/8/2026+0.00
https://www.zacks.com/stock/news/2917155/sarepta-s-q1-earnings-sales-beat-estimates-26-outlook-maintained?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2917155 · 5/7/2026+0.60
https://www.benzinga.com/trading-ideas/movers/26/03/51459948/why-is-sarepta-therapeutics-stock-exploding-today · 3/25/2026+0.80
https://247wallst.com/investing/2026/03/25/sarepta-therapeutics-zooms-20-higher-on-promising-clinical-data-is-srpt-ready-for-a-bigger-breakout/ · 3/25/2026+0.60
https://www.zacks.com/stock/news/2885296/srpt-stock-up-as-enrollment-begins-in-dmd-gene-therapy-safety-study?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2885296 · 3/17/2026-0.40
https://www.defenseworld.net/2026/02/01/sarepta-therapeutics-touts-3-year-embark-data-showing-elevidys-slows-dmd-decline-no-new-safety-flags.html · 2/1/2026+0.80
https://www.proactiveinvestors.com/companies/news/1086254 · 1/26/2026+1.00
https://www.businesswire.com/news/home/20260123635834/en/Sarepta-Therapeutics-to-Report-3-Year-Topline-Data-from-EMBARK-Study-of-ELEVIDYS-Gene-Therapy-in-Ambulatory-Individuals-with-Duchenne-Muscular-Dystrophy/ · 1/23/2026+0.10
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
